Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Michael Schweizer

Michael Schweizer MD

Assistant Professor, Division of Medical Oncology, University of Washington, Seattle, Washington

Michael Schweizer is an Assistant Professor at the University of Washington/Fred Hutchinson Cancer Research Center (UW/FHCRC) who specializes in genitourinary oncology. He received his medical degree from Temple University School of Medicine. Dr. Schweizer then went on to complete his internship and residency in internal medicine at the University of Chicago, and medical oncology fellowship at Johns Hopkins.

Dr. Schweizer is a clinical-translational researcher with a focus on early drug development for men with prostate cancer. He has been active in developing a number of novel prostate cancer therapies, including: high-dose testosterone for men with advanced prostate cancer and combination androgen ablative regimens for men with high-risk localized disease. By focusing on “high-risk, high-reward” projects, Dr. Schweizer hopes that his research will lead to new, effective therapies that will allow prostate cancer patients to live longer and better.

Recent Contributions to PracticeUpdate:

  1. Influence of Prior Abiraterone on Clinical Activity of Docetaxel in Metastatic Castration-Resistant Prostate Cancer